Lexaria Bioscience (NASDAQ: LEXX, LEXXW) is a global innovator in drug delivery platforms. The company today issued information to its stakeholders as an aid to conveniently research and understand various non-affiliated third-party sources and their methodologies for valuing biotech and pharmaceutical companies. “Biotech companies with little to no revenue can still be worth billions,” Raphael Rottgen, CFA, FRM, was quoted in the press release. “While valuations can be extremely low or extremely high, there is often underlying logic in identifying risks and arriving at those valuations. Developing new drugs can have significant costs of over $1 billion and can take as long as 10 to 15 years to reach the market.”

The announcement clarifies that Lexaria’s DehydraTECH-CBD for hypertension program is currently operating within step three of five of the drug development process according to descriptions from the U.S. Food and Drug Administration (“FDA”). Under this step, various human studies seek to evidence both tolerability/safety as well as efficacy for intended purposes. Of the 5,000 – 10,000 compounds examined and tested in the discovery phase, not more than about 250 successfully complete the preclinical research step. Lexaria’s DehydraTECH-CBD is among those successes, having already reached and surpassed the preclinical research stage.

To view the full press release, visit https://ibn.fm/LNu0j

About Lexaria Bioscience Corp.

Lexaria’s patented drug delivery technology, DehydraTECH(TM), improves the way active pharmaceutical ingredients (“APIs”) enter the bloodstream by promoting more effective oral delivery. Since 2016, DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption with cannabinoids, antiviral drugs, PDE5 inhibitors and more. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 26 patents granted and roughly 50 patents pending worldwide. For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

About TinyGems

TinyGems is your guide to the best and brightest in the under-appreciated small-cap sector. As one of 50+ brands within the InvestorBrandNetwork (“IBN”), TinyGems provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions to ensure maximum impact; (4) social media distribution via IBN to reach millions of social media followers; and (5) a full array of corporate communications solutions. It’s time to uncover some of the best-kept secrets on Wall Street. TinyGems features innovative small-cap companies with huge potential, putting a spotlight on the best and brightest of these disruptors that have the technology, the talent, the drive, and the business models to make a huge impact in the markets and in portfolios. Whether it’s a game changing technology, a new more profitable product or service, or a star in a hot sector, TinyGems is the go-to source for actionable intelligence.

To receive SMS text alerts from TinyGems, text “Gems” to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.TinyGems.net

Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.net/Disclaimer

TinyGems
Los Angeles, California
www.TinyGems.net
310.299.1717 Office
Editor@TinyGems.net

TinyGems is part of the InvestorBrandNetwork